Onxeo Announces its Financial Agenda for 2019

Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced its financial agenda for 2019.



Full-year 2018 results

Tuesday, March 12, 2019

Shareholders’ general meeting

Friday, April 26, 2019

Half-year 2019 results

Thursday, July 25, 2019


* This preliminary agenda may be modified. Press releases are published after financial markets close.